All In Biotech

Drug Trial Radar · NCT05783557

A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

A Randomized, Double-blind, Active-compared Phase Ш Clinical Trial to Evaluate Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

Last checked: Nov 20, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 398 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

398

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Dec 1, 2024

Study completion Jun 1, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, active-compared phase Ш clinical trial to evaluate clevidipine butyrate injectable emulsion in the treatment of Hypertensive Emergency and Sub-emergency.

Conditions

  • Hypertensive Emergency

Interventions

  • Clevidipine Butyrate Injectable EmulsionDrug

    intravenous injection

  • Cleviprex®Drug

    intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients whose SBP fell within the target range (SBP decreased by ≥15% and ≤25% from baseline) within 30 minutes of administrationTime frame: 30 minutes

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.